Effectiveness of Ferritin-guided Donation Intervals in Blood Donors: results of the Stepped Wedge Cluster-randomised FIND'EM Trial

Amber Meulenbeld[1,2], a.meulenbeld@sanquin.nl

Steven Ramondt[1,3], s.ramondt@sanquin.nl

Maike G. Sweegers[1], m.sweegers@nki.nl

Franke A. Quee[1,2], f.quee@sanquin.nl

Femmeke J. Prinsze[1], f.prinsze@sanquin.nl

Emiel O. Hoogendijk[4,5], e.hoogendijk@amsterdamumc.nl

Dorine W. Swinkels[6,7], dorine.swinkels@radboudumc.nl

Katja van den Hurk[1,2], k.vandenhurk@sanquin.nl

1. Donor Studies, Donor Medicine Research, Sanquin Research, Amsterdam, the Netherlands;
2. Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, Amsterdam, the Netherlands;
3. Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;
4. Department of Epidemiology and Data Science, Amsterdam Public Health research institute, Amsterdam UMC, Amsterdam, the Netherlands;
5. Department of General Practice, Amsterdam Public Health research institute, Amsterdam UMC – Location VU University medical center, Amsterdam, the Netherlands;
6. Department of Laboratory Medicine, Radboud University Nijmegen, Nijmegen, Gelderland, The Netherlands;
7. Center for Iron Disorders Sanquin, Sanquin Blood Supply Foundation, Amsterdam, Noord-Holland, The Netherlands.

Running head: FIND'EM: A stepped wedge trial of ferritin monitoring in blood donors

Words (max. 3000): 2972

Corresponding author

Amber Meulenbeld

Sanquin Research

Plesmanlaan 125

PO box 9137

1006 AC Amsterdam, the Netherlands
E-mail: a.meulenbeld@sanquin.nl

Abstract

Importance Blood donors are at increased risk for iron deficiency. Current hemoglobin (Hb) monitoring policies are inadequate and new iron management strategies are warranted.

Objective To determine the effects of ferritin-guided donation intervals for whole blood donors on Hb and ferritin levels, Hb deferral, iron deficiency (ferritin < 15 ng/mL) prevalence, donor return, and iron deficiency-related symptoms.

Design Between November 2017 and November 2019 a ferritin-guided donation interval policy was gradually implemented nationwide and evaluated through a stepped-wedge cluster-randomized controlled trial.

Setting All blood collection centers in the Netherlands.

Participants 412,888 whole blood donors were included.

Interventions Ferritin was measured in all new donors and at every 5th whole blood donation. Subsequent donation intervals were extended to six months if ferritin is 15 ≤ 30 ng/mL and to twelve months if ferritin is <15 ng/mL (iron deficient).

Main outcomes and Measures The primary outcomes are ferritin and Hb levels, iron deficiency, Hb deferral, and donor return. Secondary outcomes are self-reported iron deficiency-related symptoms.

Results We measured 36,099 donors, median age 43 years and 52% female, making 37,621 donations during the study period. Ferritin-guided donation intervals increased log-transformed ferritin levels at all time points in the trial, up to 0.56 log-transformed ng/mL as compared to baseline (*95% CI* 0.49 – 0.63, p <0.001). Hb increased as well, up to 0.39 g/dL (*95% CI* 0.32 – 0.45, p <0.001). Decreased odds of 13% (*95% CI* 8 – 22, p <0.001) for iron deficiency and 20% (*95% CI* 6 – 47, p <0.001) for Hb deferral were reported compared to baseline. Odds of donor return decreased over the course of the trial, as low as 56% (*95% CI* 48 – 66, p <0.001). We found no evidence for improved self-reported iron deficiency-related symptoms after implementation of the new policy.

Conclusion and Relevance Ferritin-guided donation intervals significantly increased overall Hb and ferritin levels, thereby decreasing the prevalence of iron deficiency and Hb deferrals in whole blood

donors. Ferritin-guided donation intervals seem beneficial for Hb levels and iron maintenance, but additional efforts are required to retain donors and to remedy self-reported iron deficiency-related symptoms.

Trial Registration This trial has been registered in the Dutch trial registry (NTR6738) on September 29th, 2017 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR6738).

Key words: blood donation, donation interval, donor health, stepped wedge cluster randomized trial, ferritin

Introduction

Annually, more than 100 million whole blood donations are made worldwide to provide life-saving treatment for patients requiring transfusion (1). However, whole blood donors that donate repeatedly are at risk of developing iron deficiency and subsequent anemia (2). Male donors lose approximately 8% of their total iron stores with each whole blood donation, whereas menstruating women can lose up to 81% of their total iron stores (3–5). Iron stores can be monitored through measuring ferritin levels. Iron deficiency, defined as ferritin levels <15 ng/ml, is present in approximately 15.0% of female and 9.4% of male Dutch repeat donors (6).

There is no consensus on strategies for donor iron management to ensure donor health. Currently, two main strategies are being used to prevent iron deficiency in whole blood donors: extending donation intervals or providing iron supplements (7–9). Negative perceptions regarding iron supplementation, adverse effects like gastrointestinal disturbances, and poor compliance could be reasons to prefer extended donation intervals over iron supplementation (9,10). In previous studies, extended donation intervals were associated with lower risk of Hb deferrals (11,12). The randomized-controlled INTERVAL trial showed that donation intervals of 12 and 16 weeks for men and women, respectively, leads to significantly higher Hb and ferritin levels compared to intervals of 8 and 12 weeks (12). Most blood establishments have implemented an Hb-based monitoring policy to protect donor health, prevent anemia and ensure a sufficient Hb content in the product, deferring blood donors with Hb levels below 13.5 g/dL (males) or 12.5 g/dL (females) (7–9,13–15). However, iron deficiency can present without low Hb, especially in repeat donors. As Hb levels do not reflect iron stores, the current standard of Hb monitoring is insufficient to ensure the maintenance of proper iron reserves and donor health. The World Health Organization (WHO) advises additional monitoring of ferritin in donors to detect iron deficiency and monitor donor health (16).

In 2017, a new nationwide policy for iron monitoring of whole blood donors was implemented by Sanquin Blood Bank in The Netherlands. In addition to the existing capillary Hb measurement at the pre-donation screening, a ferritin measurement is conducted in venous samples at the first donation of new donors and after every fifth whole blood donation of repeat donors. If ferritin levels are between 15 and 30 ng/mL or below 15 ng/mL, the subsequent donation interval is extended to six or twelve months, respectively. A stepped-wedge approach, with random cross-over of blood collection centers from the existing to the new policy, was used to evaluate the effects of this ferritin-guided donation interval policy for whole blood donors on (1) Hb and ferritin levels, (2) iron deficiency, (3) Hb deferral, (4) donor return rates, and (5) self-reported iron deficiency-related symptoms.

Methods

Design

Ferritin measurement IN Donors—Effectiveness of iron Monitoring (FIND'EM) is a stepped wedge cluster-randomized trial, described in detail by Sweegers et al. (17). During the study period, between November 2017 and November 2020, 1,643,700 donations were made by 412,888 donors. we measured ferritin levels before, during, and at full implementation (twice) in all donations made by new and repeat donors visiting a blood collection center during one pre-selected week. Stored blood samples from donors who gave permission to "use remainders of [their] donation available for medical scientific research in general" were used for ferritin measurements. Furthermore, donors were asked to read the study information and sign the informed consent forms if they were interested in completing additional questionnaires. The trial was powered on the ferritin level outcome (17). The policy and implementation strategy was reviewed and approved by Sanquin's Medical and Ethical Advisory boards. The trial was approved by Sanquin's Board of Directors.

Randomization

119 Before randomization, the 50 fixed blood collection centers in the Netherlands were divided over 29
120 blood collection clusters. These clusters were randomly assigned to four randomization groups. The
121 stepped wedge design involved random and sequential crossover of all 29 clusters, by group, from
122 the current policy to the policy including ferritin-guided donation intervals, until all clusters had
123 implemented the new policy. The allocation was not concealed and the planned timing of each
124 cluster's crossover was revealed before the study. Stepwise implementation of the new policy
125 resulted in a gradually decreasing control group and a simultaneously increasing intervention group
126 (17). Implementation started in November 2017 and was completed in November 2019.

127

128 *Procedures*

129 As part of routine procedures, donors undergo a pre-donation screening to check their eligibility to
130 donate by measuring Hb levels and blood pressure and assessment of recent travel, sexual and
131 medical history. In accordance with European legislation, Hb cut-offs for donor eligibility of > 13.5
132 g/dL for males and > 12.5 g/dL for females are used in The Netherlands (18). Donors with low Hb
133 (measured prior to donating in capillary blood with HemoCue 201, Angelholm, Sweden) are deferred
134 from donating for 3 months. If eligible, males can donate every 56 days up to five times a year,
135 females every 122 days up to three times a year.

136

137 The intervention entails extended donation intervals based on ferritin measurements. The cut-offs
138 for extended intervals were based on definitions for iron deficiency (<15 ng/mL, 12 months deferral)
139 and reduced iron levels (≤ 30 ng/mL, 6 months deferral) by Alvarez-Ossorio et al. (9). The six month
140 interval is based on the results from Schotten et al., suggesting donation intervals of at least 180 days
141 are required to fully replete the iron lost by donating (8). A twelve month interval is indicated for iron
142 deficient donors in order to replete to higher levels than pre-donation. In whole blood donors,
143 ferritin is measured at the health check before the first donation and at the pre-donation screening

144 before each fifth whole blood donation. If ferritin levels are > 30 ng/mL, donors are eligible to donate
145 at regular donation intervals. If ferritin levels are ≤ 30 ng/mL but ≥ 15 ng/mL, repeat donors are
146 deferred for six months; new donors with ferritin levels of 15-30 ng/mL at the health check are
147 allowed to donate, but ferritin is measured again at this first donation. After the first donation, new
148 donor policy follows that of repeat donors. If ferritin levels are < 15 ng/mL, new and repeat donors
149 are deferred from donating for twelve months. Ferritin levels are measured again in the donation
150 after an extended interval. Based on medical history and iron deficiency-related complaints, donor
151 physicians could advise both new and repeat donors to visit their general practitioner and/or donate
152 at a lower frequency (17).
153

154 *Outcome assessment*

155 Before the start of the trial, we defined three measurement points: 1) a week before implementation
156 (i.e., baseline), 2) a week at mid-implementation (when 55% of blood collection centers had
157 implemented the policy) and 3) a week after complete implementation of ferritin-guided donation
158 intervals. Hb and ferritin levels, Hb deferral, iron deficiency, donor return are primary outcomes, iron
159 deficiency-related symptoms are secondary outcomes. For all donors that visited a blood collection
160 center during the measurement weeks and gave consent for their information and left-over material
161 to be used for research purposes, we extracted pseudonymized age, sex, Hb levels and deferrals from
162 the donor database (eProgesa software application; MAK-SYSTEM, Paris, France). We defined donor
163 return as a donation attempt within six months after being eligible to donate again, thereby taking
164 into account minimum donation intervals and any deferrals if applicable. We measured ferritin levels
165 on the Architect i2000sr (Abbott Diagnostics) in plasma samples collected at donation in K3EDTA
166 tubes (VACUETTE®, Greiner Bio-One, Kremsmünster, Austria) and stored at -30°C.
167

New and repeat donors who visited fixed blood collection centers during the measurement period at mid-implementation and after full implementation who signed an informed consent form were asked to complete questionnaires. These questionnaires assess physical and mental wellbeing (SF-36), fatigue (Checklist Individual Strength), donation-related symptoms, restless legs syndrome (RLS) and pica, cognitive functioning (Cognitive Failure Questionnaire), and warm glow (12,17,19–22). Questionnaires could be accessed through a hyperlink or a QR-code and were completed using Qualtrics XM® software (Provo, UT, USA) during or shortly after the donation. Donors who were unable to complete the online questionnaires were provided with paper versions or sent the questionnaires through (e-)mail (17).

Data analyses

Descriptive statistics are provided for the donor population at baseline. We used ordinary least squares regression in case of continuous outcomes and logistic regression for binary outcomes. We conducted robust regression analyses for questionnaire data with continuous outcomes due to outliers. Measurements after implementation were grouped in periods of 6 months and compared to the control condition, which was defined as no implementation of the new policy or implementation less than 6 months ago. Analyses were adjusted for age, weight and height. Stratified analyses were performed to investigate differences in the effectiveness of ferritin-guided donation intervals between male and female donors. A two-sided p-value of <0.05 is considered statistically significant.

Deviations from protocol

Due to the impact of the new policy on the blood supply after implementation in the first group, further implementation executed in smaller steps (17). Additional ferritin measurements were done on samples from all donations one year after the last measurement round (between November 23rd and 27th 2020). The fourth measurement timepoint was added to enable evaluation long-term results, as effects of the policy were expected and observed to only show after a while, due to the

long deferrals and the relatively small number of donors measured at once. We furthermore deviated from the protocol by using ordinary least squares regression instead of linear mixed models after assessment of the intraclass correlation coefficient, that ranged from 0.000 to 0.007. Lastly, we conducted an additional logistic regression analysis for donor return for which we separated donors with ferritin ≤ 30 and > 30 ng/mL.

Results

A total of 412,888 whole blood donors made 1,634,700 donations during the study and implementation period. We performed additional measurements in samples of 37,621 donations by 36,099 donors (Figure 1). Table 1 shows the baseline characteristics of participating donors by sex and randomization group. Overall, across the randomization groups, donors were well balanced with respect to characteristics and comparable with the general donor population (Table 1)(23). Baseline characteristics of the 7,573 participants in the questionnaire are provided in Table S1.

Figure 2 shows that, in all groups, the prevalence of both iron deficiency and Hb deferral decreased during trial. Ferritin-guided donation intervals are associated with significantly higher ferritin and Hb levels and less iron deficiency and Hb deferrals (Table 2). Compared to pre-implementation, the intervention was associated with up to 0.56 log-transformed ng/mL higher ferritin and 0.39 g/dL higher Hb at 36 months after implementation in males (Table 2). In both premenopausal and postmenopausal females, we also observe positive associations, albeit smaller, with an increasing trend over time since implementation. Moreover, at 36 months after implementation, the odds ratio of 0.19 indicates that males are 81% less likely to be iron deficient than at pre-implementation (Table 2). In postmenopausal females, odds ratios also decrease over the course of the trial, with iron deficiency being 87% less likely at 36 months after implementation as compared to pre-implementation (Table 2). Hb deferral in males was up to 73% less likely as time since implementation increased, compared to pre-implementation. Similarly, in premenopausal females,

220 Hb deferral is up to 35% less likely at full implementation than at pre-implementation (Table 2). In
221 postmenopausal females, Hb deferral is up to 49% less likely than at pre-implementation.
222
223 The odds for donors to return within six months of the first allowed donation date are lower at each
224 timepoint after implementation compared to pre-implementation (Table 2). At 36 months after
225 implementation, males were 43% less likely to return for donation (Table 2). For premenopausal
226 females, we do not observe a clear decrease in odds over the course of the trial, while for
227 postmenopausal females, the odds to return for a donation do decrease but are not statistically
228 significant at all timepoints (Table 2). Table S2 shows that after implementation odds for return are
229 mostly lower in donors with ferritin levels ≤30 compared to donors with ferritin > 30 ng/mL.
230 However, there is no significant difference between the two groups: confidence intervals overlap at
231 most timepoints.
232
233 There was no evidence of improvement of self-reported iron deficiency-related outcomes after
234 implementation of the new policy. There were no consistent significant patterns for pica, fatigue,
235 cognitive functioning, the SF-36, and warm glow (Table 3). However, the reporting of RLS increased.
236 Compared to pre-implementation, premenopausal females, postmenopausal females, and males
237 were 185%, 111%, and 106% more likely to report RLS at 24 months after implementation than at
238 pre-implementation.
239
240 **Discussion**
241 Our stepped-wedge cluster-randomized trial among Dutch whole blood donors shows that ferritin
242 and Hb levels are significantly higher and iron deficiency and Hb deferral prevalence significantly
243 lower after the implementation of ferritin-guided donation intervals in comparison to the prior
244 standard of Hb monitoring only. Conversely, we found that the odds for donor return within six
245 months decreased substantially after implementation of this policy. The new policy did not affect

most self-reported iron deficiency related symptoms, but was associated with increased reporting of RLS.

The new policy was associated with being significantly less likely to be iron deficient and higher ferritin and Hb levels compared to pre-implementation, which aligns with findings in donor population simulations that assess the impact of ferritin testing (24). A possible explanation for the weaker effects in premenopausal females compared to other groups may be that already at pre-implementation, premenopausal females were more frequently deferred, a measure of a similar nature that is part of the pre-implementation Hb monitoring policy, and return less. This allows more recovery time from donations. Additionally, because of more stable iron stores due to the healthy donor effect, their lower donation frequency and baseline ferritin levels, the remaining pool of premenopausal donors may not show associations as strong as the other groups (25,26).

Our finding that the new policy is associated with significantly lower odds for donor return supports previous findings on the effects of deferral on donor return, but may additionally be explained by the negative effects of the COVID-19 pandemic on blood donation intentions (27–30). Return within six months for donors measured during both weeks at full implementation overlapped with lockdowns due to the COVID-19 pandemic in The Netherlands. However, the negative association of the new policy with donor return in premenopausal females was weaker compared to other groups, which may be explained by their exposure to more frequent deferral through the old Hb monitoring policy.

The increased reporting of RLS seems surprising, but may simply be a result of an increased awareness as a result of information provided to the donor upon implementation. Further investigation shows no statistically significant correlation between RLS and ferritin levels. The lack of improvement we found in self-reported iron deficiency-related symptoms aligns with previous randomized placebo-controlled trials investigating the effects of iron repletion, albeit through iron

supplementation, on self-reported donor health (31–33). In addition, the steady reduction in iron deficiency and Hb deferral may have delayed positive effects on self-reported iron deficiency-related symptoms, which would require longer follow-up in future studies.

Our findings raise important policy and practical considerations. First, our results suggest that a ferritin-guided donation interval policy effectively reduces iron deficiency and Hb deferral in whole blood donors. This supports the WHO's advice to conduct additional monitoring of ferritin to detect iron deficiency and monitor donor health (16). Furthermore, it provides policymakers with a monitoring option that requires no effort from blood donors, may be more effective in protecting donor's iron status than standard Hb monitoring practices and does not impose a risk of side effects as related to iron supplementation (10). However, the decreasing odds of donor return stresses the need for intensified efforts to retain donors after implementation of this policy, specifically in donors whose intervals were extended. We encourage intensified donor recruitment with the implementation of prolonged donation intervals to ensure the continuity of the blood supply, because of the effects on donor return and decreased donor availability due to the prolonged donation intervals (34). Iron supplementation can be considered as an alternative or additional strategy, as it may involve less deferral and extended donation intervals and thus benefit donor availability (24,35). Nevertheless, there are also long-term benefits to a ferritin-guided donation interval policy: initial evaluations and the results presented here suggests that donors subjected to this policy might be deferred less often on site and are less likely to discontinue their donor career, resulting in a more stable donor pool (34).

To our knowledge, this is the first randomized study that goes beyond the limitations of Hb monitoring by evaluating the effectiveness of ferritin-guided donation intervals in improving Hb and ferritin levels, donor return rates and decreasing iron deficiency, Hb deferrals, and iron deficiency-related symptoms. One of the major strengths of this trial is the stepped wedge cluster-randomized

approach as it allows simultaneous implementation and evaluation of a new policy. However, there are also limitations to this study. The nature of the intervention poses a risk of overestimating the positive effect of ferritin-guided donation intervals. Donors with low ferritin, whose donation intervals are extended, may not return frequently, potentially resulting in selection bias. However, the risk of overestimation is to some extent minimized as the duration of the trial exceeds the length of extended donation intervals. There may even be underestimation of the effect on iron deficiency, as cut-offs for iron deficiency used in this study are lower than suggested in literature (36,37). Furthermore, even though donor loss may be detrimental for the blood supply, extended intervals could be beneficial for the health of donors struggling to maintain sufficient iron levels. There may also be more delayed effects of this trial, because ferritin levels are measured once every five donations, which delays individual donors' actual encounter with the policy.

The FIND'EM study provides substantial evidence that ferritin-guided donation intervals increase Hb and ferritin levels and thereby effectively prevent iron deficiency and Hb deferral. Further efforts are needed to counteract the negative effects on donor return and to investigate long-term effects on donor health outcomes. Our results may help blood services worldwide to improve their donor iron management policies in order to protect donors from developing iron deficiency.

Declarations

Ethics approval and consent to participate

Sanquin's Ethical Advisory Board has reviewed and approved the FIND'EM protocol. Only data from donors who gave consent for their information and left-over material to be used for research purposes at the health check were included in the study. Donors who completed questionnaires provided informed consent for their questionnaire data to be matched with data from the donor database.

Competing interests

The authors declare that they have no competing interests.

Funding

The current project is supported by the 'Product and Process Development Cellular Products Grant' (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee, Sanquin, Amsterdam, The Netherlands.

Authors' contributions

KvdH designed the study. KvdH, MS, FP and FQ set up and coordinated data collection. AM, and SR wrote the analysis plan and drafted the manuscript. AM, SR and FP conducted the analyses with support from EH. The manuscript was critically reviewed and approved by all co-authors.

Acknowledgements

We would like to acknowledge all blood bank staff for their commitment to the implementation of the policy and their efforts in collecting data for our study. We are thankful to all donors for their contribution to the study.

References

1. WHO. Blood safety and availability [Internet]. Beschikbaar op: https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability

2. Prinsze FJ, de Groot R, Timmer TC, Zalpuri S, van den Hurk K. Donation-induced iron depletion is significantly associated with low hemoglobin at subsequent donations. Transfusion. 2021;61(12):3344–52.

3. Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion. Transfus Med. 2008;18(1):13–27.

4. Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. Transfusion. 2006;46(10):1667–81.

5. Brittenham GM. Iron balance in the red blood cell donor. Dev Biol (Basel). 2005;120:77–82.

6. Vinkenoog M, van den Hurk K, van Kraaij M, van Leeuwen M, Janssen MP. First results of a ferritin-based blood donor deferral policy in the Netherlands. Transfusion. 60(8):1785–92.

7. Boulton F. Managing donors and iron deficiency. Vox Sang. 2004;87 Suppl 2:22–4.

8. Schotten N, Pasker-de Jong PC, Moretti D, Zimmermann MB, Geurts-Moespot AJ, Swinkels DW, e.a. The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism. Blood. 2016;128(17):2185–8.

9. Alvarez-Ossorio, Kirchner, Klüter, Schlenke. Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfusion Medicine. 1 juni 2000;10(2):107–12.

10. Smith GA, Fisher SA, Doree C, Di Angelantonio E, Roberts DJ. Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. Cochrane Database Syst Rev. 2014;(7):CD009532.

11. Baart AM, van den Hurk K, de Kort WL. Minimum donation intervals should be reconsidered to decrease low hemoglobin deferral in whole blood donors: an observational study. Transfusion. 2015;55(11):2641–4.

12. Di Angelantonio E, Thompson SG, Kaptoge S, Moore C, Walker M, Armitage J, e.a. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. Lancet. 2017;390(10110):2360–71.

13. Spencer B. Blood donor iron status: are we bleeding them dry? Curr Opin Hematol. 2013;20(6):533–9.

14. Simon TL, Garry PJ, Hooper EM. Iron stores in blood donors. Jama. 1981;245(20):2038–43.

15. Cable RG, Brambilla D, Glynn SA, Kleinman S, Mast AE, Spencer BR, e.a. Effect of iron supplementation on iron stores and total body iron after whole blood donation. Transfusion. 2016;56(8):2005–12.

16. WHO. Guidelines on Assessing Donor Suitability for Blood Donation. In: Blood Donor Selection [Internet]. Geneva; 2012. Beschikbaar op: https://www.ncbi.nlm.nih.gov/pubmed/23700651

17. Sweegers MG, Zalpuri S, Quee FA, Huis in 't Veld EMJ, Prinsze FJ, Hoogendijk EO, e.a. Ferritin measurement IN Donors—Effectiveness of iron Monitoring to diminish iron deficiency and low haemoglobin in whole blood donors (FIND'EM): study protocol for a stepped wedge cluster randomised trial. Trials. 2020;21(1):823.

18. European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). Guide to the preparation, use and quality assurance of blood components. European Directorate for the Quality of Medicines and HealthCare; 2017.

19. Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

20. Vercoulen JHMM; SCMA; FJFM; GJMD; van der MJWM; BG. de Checklist Individual Strength (CIS). Gedragstherapie. 1999;32:131–6.

21. Van den Hurk K, Peffer K, Habets K, Atsma F, Pasker-de Jong PCM, Van Noord PAH, e.a. Blood donors' physical characteristics are associated with pre- and post-donation symptoms - Donor InSight. Blood Transfus. 2017;15(5):405–12.

22. Ferguson E, Atsma F, de Kort W, Veldhuizen I. Exploring the pattern of blood donor beliefs in first-time, novice, and experienced donors: differentiating reluctant altruism, pure altruism, impure altruism, and warm glow. Transfusion. 2012;52(2):343–55.

23. Timmer TC, de Groot R, Habets K, Merz EM, Prinsze FJ, Atsma F, e.a. Donor InSight: characteristics and representativeness of a Dutch cohort study on blood and plasma donors. Vox Sang. 2019;114(2):117–28.

24. Richard P, Fillet A, Malard L, Leclerc C, Chanut C, Woimant G, e.a. Impact of donor ferritin testing on iron deficiency prevention and blood availability in France: A cohort simulation study. Vox Sanguinis. januari 2023;118(1):24–32.

25. Moazzen S, sweegers M, Hogema B, Hoekstra T, van den Hurk K. Ferritin trajectories over repeated whole blood donations: results from the FIND+ study. medRxiv. 2021;2021.12.13.21267744.

26. Atsma F, Veldhuizen I, Verbeek A, de Kort W, de Vegt F. Healthy donor effect: its magnitude in health research among blood donors. Transfusion. 2011;51(8):1820–8.

27. Spekman MLC, Tilburg TG, Merz E. Do deferred donors continue their donations? A large-scale register study on whole blood donor return in the Netherlands. Transfusion. december 2019;59(12):3657–65.

28. Custer B, Chinn A, Hirschler NV, Busch MP, Murphy EL. The consequences of temporary deferral on future whole blood donation. Transfusion. 2007;47(8):1514–23.

29. Custer B, Schlumpf KS, Wright D, Simon TL, Wilkinson S, Ness PM, e.a. Donor return after temporary deferral. Transfusion. 2011;51(6):1188–96.

30. Veseli B, Sandner S, Studte S, Clement M. The impact of COVID-19 on blood donations. Dickert S, redacteur. PLoS ONE. 24 maart 2022;17(3):e0265171.

31. Hod EA, Brittenham GM, Bitan ZC, Feit Y, Gaelen JI, La Carpia F, e.a. A randomized trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and well-being. Blood. 22 december 2022;140(25):2730–9.

32. Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Cornuz J, Tissot JD, e.a. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. BMC Med. 2012;10:8.

33. Keller P, von Känel R, Hincapié CA, da Costa BR, Jüni P, Erlanger TE, e.a. The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial. Sci Rep. 26 augustus 2020;10(1):14219.

34. Spekman MLC, Ramondt S, Sweegers MG. Whole blood donor behavior and availability after deferral: Consequences of a new ferritin monitoring policy. Transfusion. april 2021;61(4):1112–21.

35. Karregat J, Sweegers MG, Quee FA, Weekamp HH, Swinkels DW, Novotny VMJ, e.a. Ferritin-guided iron supplementation in whole blood donors: optimal dosage, donor response, return and efficacy (FORTE)-a randomised controlled trial protocol. BMJ Open. 2022;12(3):e056316–e056316.

36. Galetti V, Stoffel NU, Sieber C, Zeder C, Moretti D, Zimmermann MB. Threshold ferritin and hepcidin concentrations indicating early iron deficiency in young women based on upregulation of iron absorption. EClinicalMedicine. september 2021;39:101052.

37. Tarancon-Diez L, Genebat M, Roman-Enry M, Vázquez-Alejo E, Espinar-Buitrago M de la S, Leal M, e.a. Threshold Ferritin Concentrations Reflecting Early Iron Deficiency Based on Hepcidin and Soluble Transferrin Receptor Serum Levels in Patients with Absolute Iron Deficiency. Nutrients. 10 november 2022;14(22):4739.

Table 1. Donor characteristics at baseline

	Group 1[1]	Group 2	Group 3	Group 4	Overall
Pre-menopausal, female donors	N = 688	N = 590	N = 634	N = 465	N = 2,377
New donors, N (%)	167 (24.3)	109 (18.5)	131 (20.7)	86 (18.5)	493 (20.7)
Age (years), median [IQR]	25.0 [21.0, 31.0]	26.0 [21.0-34.0]	26.0 [22.0-33.8]	25.0 [21.0-31.0]	25.0 [21.0-33.0]
Height (cm), mean (SD)	171 (6.4)	171 (6.9)	171 (6.3)	171 (6.4)	171 (6.5)
Weight (kg), mean (SD)	71.0 (12.2)	69.0 (12.4)	71.4 (11.9)	70.8 (12.1)	71.1 (12.2)
Hemoglobin, median [IQR], g/dL	13.4 [12.7-12.4]	12.4 [12.9-12.1]	13.5 [12.9-14.0]	13.4 [12.9-14.0]	13.4 [12.9-14.0]
Low hemoglobin deferral (<12.5 g/dL), N (%)	64 (9.3)	34 (5.8)	46 (7.3)	43 (9.2)	187 (7.9)
Ferritin, median [IQR], ng/mL	26.2 [13.3-46.2]**	24.7 4 [12.1-46.7]**	24.7 [12.7-45.5]**	23.7 [10.3-40.3]**	25.1 [12.3-45.4]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	161 (23.4)**	159 (26.9)**	173 (27.3)**	130 (28.0)**	623 (26.2)**
Total number of whole blood donations, median [IQR]	2.0 [1.0-7.0]	3.0 [1.0-9.0]	4.0 [1.0-10.0]	3.0 [1.0-9.0]	3.0 [1.0-9.0]
Number of whole blood donations in the past 2 years, median [IQR]	2.0 [1.0-4.0]	2.0 [1.0-4.0]	2.0 [1.0-4.0]	3.0 [1.0-4.0]	2.0 [1.0-4.0]
Donor return within 6 months of first allowed date, N (%)	478 (66.5)	383 (64.9)	436 (68.8)	323 (69.5)	1,620 (68.2)
Post-menopausal, female donors	N = 388	N = 379	N = 387	N = 308	N = 1,462
New donors, N (%)	11 (2.8)	7 (1.8)	13 (3.4)	2 (0.6)	33 (2.3)
Age (years), median [IQR]	55.0 [49.0-60.0]	55.0 [50.0-61.0]	56.0 [49.0-60.0]	55.0 [49.8-62.0]	55.0 [50.0-61.0]
Height (cm), mean (SD)	170 (5.9)	169 (6.1)	170 (6.2)	170 (5.9)	170 (6.0)
Weight (kg), mean (SD)	74.5 (11.3)	73.4 (12.3)	73.9 (12.4)	73.3 (11.6)	73.8 (11.9)
Hemoglobin, median [IQR], g/dL	12.9 [13.1-14.5]	13.5 [13.1-14.5]	13.7 [13.1-14.3]	13.5 [13.1-14.3]	13.7 [13.1-14.3]
Low hemoglobin deferral (<12.5 g/dL), N (%)	19 (4.9)	19 (5.0)	21 (5.4)	11 (3.6)	70 (4.8)
Ferritin, median [IQR], ng/mL	27.4 [13.5-44.0]***	28.3 [14.0-45.8]**	25.7 [13.2-45.0]**	26.7 [15.0-43.6]**	27.4 [13.7-45.0]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	85 (21.9)***	87 (23.0)**	95 (24.5)**	64 (20.8)**	331 (22.6)**
Total number of whole blood donations, median [IQR]	29.0 [11.0-50.0]	26.0 [12.0-42.0]	29.0 [12.0-46.0]	29.0 [12.0-47.0]	28.0 [12.0-46.0]
Number of whole blood donations in the past 2 years, median [IQR]	5.0 [3.0-5.0]	4.0 [3.0-5.0]	5.0 [3.0-6.0]	5.0 [3.0-5.0]	5.0 [3.0-6.0]
Donor return within 6 months of first allowed date, N (%)	297 (76.5)	292 (77.0)	310 (80.1)	237 (76.9)	1,136 (77.7)
Male donors	N = 1075	N = 1061	N = 1007	N = 870	N = 4,013
New donors, N (%)	58 (5.4)	63 (5.9)	46 (4.6)	47 (5.4)	214 (5.3)
Age (years), median [IQR]	48.0 [32.0-58.5]	51.0 [35.0-60.0]	49.0 [32.5-58.0]	49.0 [31.0-59.0]	49.0 [32.0-59.0]
Height (cm), mean (SD)	184 (7.1)	183 (7.2)	183 (6.9)	183 (7.5)	183 (7.2)
Weight (kg), mean (SD)	86.5 (12.1)	85.8 (12.2)	85.4 (12.0)	85.4 (11.9)	85.8 (12.1)
Hemoglobin, median [IQR], g/dL	14.8 [14.2-15.6]	14.8 [14.2-15.6]	14.8 [14.2-15.6]	14.8 [14.2-15.5]	14.8 [14.2-15.6]
Low hemoglobin deferral (<13.5 g/dL), N (%)	42 (3.9)	27 (2.5)	34 (3.4)	27 (3.1)	130 (3.2)
Ferritin, median [IQR], ng/mL	25.3 [12.3-54.9]**	25.9 [13.2-55.3]**	24.8 [12.4-50.0]**	24.5 [11.6-54.8]**	25.2 [12.4-53.2]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	280 (26.0)**	273 (25.7)**	272 (27.0)**	243 (27.9)**	1,068 (26.6)**
Total number of whole blood donations, median [IQR]	30.0 [7.0-68.0]	39.0 [8.0-71.0]	32.0 [8.0-64.0]	31.5 [7.0-70.0]	32.0 [7.0-68.0]
Number of whole blood donations in the past 2 years, median	6.0 [4.0-9.0]	6.0 [4.0-9.0]	6.0 [4.0-8.0]	6.0 [4.0-8.0]	6.0 [4.0-8.0]

[IQR]					
Donor return within 6 months of first allowed date, N (%)	924 (86.0)	905 (85.3)	870 (86.4)	738 (84.8)	3,437 (85.6)

[1]Randomly assigned clusters of donation centres (Group 1-3: 8 clusters, group 4: 5 clusters)

Missing: * < 10%, ** 10-20%, *** > 20%

Table 2. Associations of implementation of ferritin-guided donation intervals with primary study outcomes.

			Time since implementation					
Outcome	Group		6-11 months[1]	12-17 months	18-23 months	24-29 months	30-35 months	36+ months
Ferritin (ng/mL, log-transformed)	PRE[2]	Coef (95% CI)	0.04 (-0.03 – 0.12)	**0.12 (0.07 – 0.18)**	**0.15 (0.07 – 0.22)**	**0.20 (0.13 – 0.27)**	**0.23 (0.12 – 0.34)**	**0.34 (0.25 – 0.44)**
	POST[3]		**0.13 (0.04 – 0.22)**	**0.22 (0.15 – 0.28)**	**0.28 (0.19 – 0.37)**	**0.34 (0.26 – 0.42)**	**0.40 (0.27 – 0.53)**	**0.55 (0.45 – 0.65)**
	Males		**0.22 (0.16 – 0.28)**	**0.41 (0.36 – 0.45)**	**0.46 (0.40 – 0.52)**	**0.53 (0.48 – 0.59)**	**0.54 (0.45 – 0.62)**	**0.56 (0.49 – 0.63)**
Iron deficiency[4]	PRE	OR (95% CI)	1.07 (0.90 – 1.26)	**0.78 (0.68 – 0.89)**	**0.71 (0.59 – 0.85)**	**0.66 (0.56 – 0.79)**	**0.61 (0.46 – 0.80)**	**0.39 (0.30 – 0.51)**
	POST		**0.77 (0.59 – 0.98)**	**0.56 (0.46 – 0.68)**	**0.40 (0.29 – 0.55)**	**0.38 (0.28 – 0.50)**	**0.35 (0.21 – 0.55)**	**0.13 (0.08 – 0.22)**
	Males		**0.51 (0.43 – 0.60)**	**0.28 (0.24 – 0.32)**	**0.21 (0.17 – 0.27)**	**0.15 (0.12 – 0.19)**	**0.15 (0.10 – 0.21)**	**0.19 (0.15 – 0.25)**
Hemoglobin (g/dL)	PRE	Coef (95% CI)	0.03 (-0.03 – 0.10)	**0.06 (0.02 – 0.11)**	**0.16 (0.10 – 0.23)**	**0.18 (0.11 – 0.23)**	-0.02 (-0.10 – 0.06)	**0.18 (0.10 – 0.24)**
	POST		0.08 (-0.02 – 0.18)	0.05 (-0.02 – 0.13)	**0.21 (0.11 – 0.29)**	**0.19 (0.11 – 0.27)**	0.00 (-0.13 – 0.13)	**0.15 (0.05 – 0.24)**
	Males		**0.15 (0.08 – 0.21)**	**0.24 (0.19 – 0.29)**	**0.31 (0.24 – 0.37)**	**0.35 (0.29 – 0.40)**	**0.29 (0.19 – 0.37)**	**0.39 (0.32 – 0.45)**
Hemoglobin deferral[5]	PRE	OR (95% CI)	0.81 (0.60 – 1.07)	0.84 (0.69 – 1.03)	**0.53 (0.38 – 0.73)**	**0.63 (0.47 – 0.83)**	**0.58 (0.37 – 0.86)**	**0.65 (0.46 – 0.90)**
	POST		0.78 (0.45 – 1.25)	0.40 (0.51 – 1.05)	0.66 (0.36 – 1.11)	**0.51 (0.29 – 0.85)**	1.03 (0.52 – 1.86)	**0.53 (0.28 – 0.93)**
	Males		0.80 (0.54 – 1.14)	**0.49 (0.35 – 0.67)**	**0.36 (0.20 – 0.59)**	**0.35 (0.21 – 0.54)**	**0.20 (0.06 – 0.47)**	**0.27 (0.14 – 0.49)**
Donor return[6]	PRE	OR (95% CI)	**0.75 (0.65 – 0.87)**	**0.86 (0.77 – 0.96)**	**0.80 (0.69 – 0.92)**	**0.74 (0.65 – 0.85)**	**0.81 (0.67 – 0.98)**	0.90 (0.77 – 1.06)
	POST		0.82 (0.65 – 1.02)	**0.84 (0.72 – 0.99)**	**0.66 (0.53 – 0.82)**	**0.68 (0.56 – 0.83)**	0.76 (0.56 – 1.03)	0.80 (0.64 – 1.01)
	Males		**0.80 (0.65 – 0.95)**	0.90 (0.80 – 1.03)	**0.66 (0.56 – 0.77)**	**0.66 (0.57 – 0.76)**	**0.68 (0.55 – 0.84)**	**0.56 (0.48 – 0.66)**

Bold text indicates significance at $p < 0.05$; all analyses are scaled and adjusted for age, height, and weight

[1] Reference group: no implementation or 0-5 months since implementation

[2] PRE: Premenopausal females (age ≤ 48)

[3] POST: Postmenopausal females (age > 48)

[4] Ferritin < 15 ng/mL

[5] For males ≥ 13.5 g/dL, for females ≥ 12.5 g/dL

[6] Within six months of the first allowed date for the next donation

Table 3. Associations of implementation of ferritin guided donation intervals with secondary study outcomes.

			Time since implementation			
Outcome	Group		6-11 months[1]	12-17 months	18-23 months	24+ months
Restless legs syndrome	PRE[2]	OR (95% CI)	**1.66 (1.01 – 2.70)**	1.12 (0.64 – 1.92)	**2.61 (1.54 – 4.33)**	**2.85 (1.82 – 4.48)**
	POST[3]		**2.11 (1.35 – 3.27)**	0.55 (0.28 – 1.00)	1.06 (0.47 – 2.12)	**2.06 (1.22 – 3.41)**
	Males		1.25 (0.80 – 1.91)	0.87 (0.53 – 1.37)	**1.89 (1.14 – 3.03)**	**1.69 (1.13 – 2.51)**
Pica	PRE[1]	OR (95% CI)	1.06 (0.29 – 2.18)	0.75 (0.29 – 1.67)	1.28 (0.50 – 2.88)	0.80 (0.29 – 1.86)
	POST2		0.53 (0.08 – 2.05)	1.66 (0.60 – 4.38)	1.62 (0.25 – 6.31)	1.93 (0.52 – 5.87)
	Males		0.68 (0.32 – 1.31)	1.00 (0.55 – 1.72)	1.11 (0.48 – 2.25)	0.91 (0.47 – 1.65)
Fatigue[4]	PRE	Coef (95% CI)	-0.33 (-1.05 – 0.39)	0.71 (-0.03 – 1.44)	-0.86 (-1.75 – 0.04)	-0.38 (-1.17 – 0.42)
	POST		-0.29 (-1.09 – 0.51)	0.32 (-0.45 – 1.09)	-0.16 (-1.31 – 1.00)	-0.49 (-1.54 – 0.55)
	Males		-0.40 (-0.92 – 0.12)	-0.50 (-1.01 – 0.01)	-0.78 (-1.61 – 0.04)	-0.27 (-0.82 – 0.28)
Cognitive functioning[4]	PRE	Coef (95% CI)	0.14 (-1.35 – 1.64)	-1.46 (-2.94 – 0.03)	-0.92 (-2.62 – 0.77)	0.87 (-0.82 – 2.56)
	POST		0.87 (-0.77 – 2.51)	1.08 (-0.50 – 2.67)	2.59 (-0.06 – 5.23)	0.86 (-1.12 – 2.84)
	Males		0.05 (-1.04 – 1.13)	0.81 (-0.29 – 1.90)	-0.59 (-2.14 – 0.96)	-0.24 (-1.38 – 0.90)
Physical health (SF-36)[5]	PRE	Coef (95% CI)	-0.04 (-0.76 – 0.68)	0.32 (-0.39 – 1.04)	0.11 (-0.79 – 1.00)	-0.64 (-1.47 – 0.19)
	POST		-0.33 (-1.32 – 0.66)	**-1.12 (-2.14 – -0.09)**	-1.01 (-2.57 – 0.54)	0.78 (-0.43 – 1.98)
	Males		-0.43 (-0.98 – 0.12)	-0.47 (-1.00 – 0.07)	-0.35 (-1.07 – 0.37)	-0.12 (-0.64 – 0.40)
Mental health (SF-36)[5]	PRE	Coef (95% CI)	**-1.25 (-2.25 – -0.24)**	-0.04 (-1.01 – 0.92)	-1.29 (-2.90 – 0.32)	-0.98 (-2.14 – 0.18)
	POST		-0.25 (-1.20 – 0.79)	0.30 (-0.75 – 1.34)	-1.37 (-3.16 – 0.42)	0.06 (-1.13 – 1.24)
	Males		0.10 (-.56 – 0.75)	-0.46 (-1.13 – 0.22)	-0.16 (-1.10 – 0.79)	0.925 (-1.02 – 0.34)
Warm glow	PRE	OR (95% CI)	0.99 (0.77 – 1.26)	**1.41 (1.11 – 1.80)**	1.03 (0.75 – 1.40)	1.06 (0.81 – 1.39)
	POST		0.86 (0.63 – 1.18)	0.80 (0.60 – 1.07)	**0.43 (0.27 – 0.68)**	0.90 (0.62 – 1.34)
	Males		0.83 (0.67 – 1.02)	0.97 (0.79 – 1.19)	**0.72 (0.55 – 0.95)**	0.81 (0.65 – 1.00)

Bold text indicates significance at $p < 0.05$; all analyses are adjusted for age, height, and weight
[1] Reference group: no implementation or 0-5 months since implementation
[2] PRE: Premenopausal females
[3] POST: Postmenopausal females
[4] Higher score indicates worse result
[5] Higher score indicates better result


Males
% low ferritin deferral
% low Hb deferral
80
60
40
20
0
8
6
4
2
0
0-5
6-11
12-17
18-23
24-29
30-35
36+
Time since intervention (months)


Premenopausal females
% low ferritin deferral
% low Hb deferral
80
60
40
20
0
8
6
4
2
0
0-5
6-11
12-17
18-23
24-29
30-35
36+
Time since intervention (months)


Postmenopausal females
% low ferritin deferral
% low Hb deferral
80
60
40
20
0
8
6
4
2
0
0-5
6-11
12-17
18-23
24-29
30-35
36+
Time since intervention (months)


Baseline measurement n = 9,180
Mid-implementation measurement n = 9,292
Full implementation measurement 1 n = 9,392
Full implementation measurement 2 n = 9,757
Group 1
Group 2A
Group 2B
Group 3A
Group 3B
Group 4
n = 451,955
n = 253,105
n = 208,808
n = 249,461
n = 178,487
n = 301,884
Control
Intervention
Nov 2017
May 2018
Oct 2018
Mar 2019
Oct 2019
Nov 2019
Nov 2020
Total: n = 1,643,700